NR4A1 and neoplasm: In patients with tumours expressing only one hormone receptor, this benefit was not observed: the 10-year adapted disease-free survival was 63.7% (95% CI 56.1–70.4) in the 6-year treatment group and 70.9% (95% CI 63.9–76.8) in the 3-year treatment group (HR 1.22; 95% CI 0.86–1.73) (Figs. 3 and 4B).